Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial
et al., Indian Journal of Rheumatology, doi:10.4103/injr.injr_264_21, NCT04867226 (history)
, Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial, Indian Journal of Rheumatology, doi:10.4103/injr.injr_264_21, NCT04867226
Open label RCT of colchicine showing improved recovery with treatment. Only the abstract is currently available. Colchicine 0.5mg bid for 14 days.
This study is excluded in the after exclusion results of meta
analysis:
minimal details provided.
|
hospitalization time, 24.1% lower, relative time 0.76, p = 0.009, treatment 36, control 44.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Jalal et al., 5 May 2022, Randomized Controlled Trial, Iraq, peer-reviewed, 3 authors, study period 8 May, 2021 - 18 June, 2021, trial NCT04867226 (history).
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.